A randomized, balanced, two-treatment, two-sequence, single oral dose, two stage crossover adaptative bioequivalence study of Rifaximin 200 mg film-coated tablets (Antibiotice SA) vs. Normix® 200 mg, film- coated tablets (Alfasigma S.P.A) in healthy subjects under fed conditions

2025-525078-12-00 Protocol RIFAAIS 01-2025 Human pharmacology (Phase I) - Bioequivalence study Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites · Protocol RIFAAIS 01-2025

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Authorised, recruitment pending
Participants planned 64
Countries 1
Sites 1

healthy subjects

Key facts

Sponsor
Antibiotice S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Bacterial Infections and Mycoses [C01], Diseases [C] - Digestive System Diseases [C06]
Decision date (initial)
2026-05-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

healthy subjects

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Antibiotice S.A.

Sponsor organisation
Antibiotice S.A.
Address
Str Valea Lupului Nr 1
City
Iasi
Postcode
707410
Country
Romania

Scientific contact point

Organisation
Antibiotice S.A.
Contact name
Clinical Trails Center

Public contact point

Organisation
Antibiotice S.A.
Contact name
Clinical Trails Center

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Romania Authorised, recruitment pending 64 1
Rest of world 0

Investigational sites

Romania

1 site · Authorised, recruitment pending
Antibiotice S.A.
Clinical Trails Center, Str Valea Lupului Nr 1, 707410, Iasi

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-02-18 Romania Acceptable
2026-05-22
2026-05-22